Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • Analysts issue BUY ratings with price targets implying up to 46.15% upside.

  • JDG's organic revenue up 7% in H1 2025 despite headwinds in North America.

  • Adjusted EPS projected to rise 15% in H1, driven by recovery at Geotek.

Judges Scientific PLC (LSE:JDG.L) has received BUY recommendations from top analysts despite a mixed trading update for the first half of 2025. As per EODHD/Others data, the company currently has a consensus price target of AUD 191.67, with the most bullish analyst seeing a potential upside of 46.15%.

Recent analyst recommendations include:

  • Scott K. Cagehin (Investec Bank UK PLC): BUY with AUD 194.62 target (+46.15%)

  • Andrew M. Simms (Berenberg): BUY with AUD 161.84 target (+21.54%)

  • Vanessa Jeffriess (Jefferies): BUY with AUD 151.19 target (+13.54%)

These ratings reflect continued institutional confidence in Judges Scientific, even as short-term trading pressures weigh on performance.

US Weakness Dampens H1 2025

The Group reported that its performance for the six-month period ended 30 June 2025 was materially impacted by U.S. market softness, primarily due to cuts in federal research funding. This challenge was previously flagged in its FY24 results and has now affected recovery expectations.

Despite these headwinds, organic order intake increased by 4% versus H1 2024, with significant performance across most regions except North America (-18%) and the UK (-7%). The organic order book stood at 17.4 weeks, slightly up from H1 2024 (17.2 weeks).

Organic Revenue Up 7%, Geotek Leads Profit Recovery

One of the key positive developments was the 7% increase in organic revenue, largely supported by the successful completion of a major coring expedition in Japan. Geotek, which had a difficult 2024, reported a recovery and contributed significantly to H1 profitability.

However, when excluding Geotek, the organic businesses faced a 7% revenue decline, with EBIT falling by one-third due to market and operational challenges in select units.

Still, adjusted earnings per share (EPS) for H1 2025 is expected to grow by around 15%, underlining resilience in the broader portfolio.

Full-Year EPS Guidance Revised; Strategic Focus Remains on Recovery

While Judges Scientific remains committed to long-term growth, the Board has revised its FY25 adjusted EPS guidance to between 285p and 330p, reflecting the impact of sector-wide pressures and internal challenges.

The company acknowledged the difficult environment, especially in the U.S., but noted that its Executive Committee is actively driving improvements and innovation across all business units.

Despite short-term turbulence, analysts remain optimistic about Judges Scientific’s growth trajectory.